Title: Multicentre prospective study to evaluate effectiveness and safety of gel-forming
and hyaluronic-acid containing chewable tablets as add-on treatment in patients with
gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor
therapy.
Version: 1 Date: 12 May 2023
Reviewer's report:
Dear Authors,
There has been no definition of "unsatisfied GERD". It is difficult to conduct the study in patients
with unclear definition of disease as the outcome measurement is not relevant . Moreover, these
important sentences still have no citation in the manuscript "Sobrade® chewable tablet is a
preparation with a solely physical mode of action and classified as a medical device of lowest
risk (Class 1). It prevents the esophageal mucosa from further GERD induced damages by
a bioadhesive coating through xanthan and carbomer whereby the comprised hyaluronic acid
supports the healing process. Thus, it acts as a symptomatically treatment by exerting efficient
protection of the esophageal mucosa and supports the re-epithelization of irritated areas.".
Title: Multicentre prospective study to evaluate effectiveness and safety of gel-forming
and hyaluronic-acid containing chewable tablets as add-on treatment in patients with
gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor
therapy.
Version: 1 Date: 12 May 2023
Reviewer's report:
Dear Authors,
There has been no definition of "unsatisfied GERD". It is difficult to conduct the study in patients
with unclear definition of disease as the outcome measurement is not relevant . Moreover, these
important sentences still have no citation in the manuscript "Sobrade® chewable tablet is a
preparation with a solely physical mode of action and classified as a medical device of lowest
risk (Class 1). It prevents the esophageal mucosa from further GERD induced damages by
a bioadhesive coating through xanthan and carbomer whereby the comprised hyaluronic acid
supports the healing process. Thus, it acts as a symptomatically treatment by exerting efficient
protection of the esophageal mucosa and supports the re-epithelization of irritated areas.".
Please review this paper.
user
Title: Multicentre prospective study to evaluate effectiveness and safety of gel-forming
and hyaluronic-acid containing chewable tablets as add-on treatment in patients with
gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor
therapy.
Version: 1 Date: 12 May 2023
Reviewer's report:
Dear Authors,
There has been no definition of "unsatisfied GERD". It is difficult to conduct the study in patients
with unclear definition of disease as the outcome measurement is not relevant . Moreover, these
important sentences still have no citation in the manuscript "Sobrade® chewable tablet is a
preparation with a solely physical mode of action and classified as a medical device of lowest
risk (Class 1). It prevents the esophageal mucosa from further GERD induced damages by
a bioadhesive coating through xanthan and carbomer whereby the comprised hyaluronic acid
supports the healing process. Thus, it acts as a symptomatically treatment by exerting efficient
protection of the esophageal mucosa and supports the re-epithelization of irritated areas.".
assistant